Antimicrobial Agents — MCQs

Antimicrobial Agents Indian Medical PG Practice Questions and MCQs

Question 161: AZT, ddI, and HAART are combinations of three drugs used in AIDS. What is their primary mechanism of action?

A. Inhibitory effects on viral DNA
B. Nucleoside reverse transcriptase inhibitors (Correct Answer)
C. Inhibit the synthesis of group 24
D. P53 anti-apoptotic molecule synthesis

Explanation: **Explanation:** The drugs mentioned, **AZT (Zidovudine)** and **ddI (Didanosine)**, belong to the class of **Nucleoside Reverse Transcriptase Inhibitors (NRTIs)**. These are structural analogs of native nucleosides. Once they enter the cell, they are phosphorylated into active triphosphate forms. They compete with natural deoxynucleotides for incorporation into the growing viral DNA chain by the enzyme **Reverse Transcriptase**. Since they lack a 3'-OH group, they cause **premature chain termination**, effectively halting viral replication. **HAART** (Highly Active Antiretroviral Therapy) is the standard treatment regimen that typically combines two NRTIs with a third drug (like a Protease Inhibitor or NNRTI) to suppress viral load and prevent resistance. **Analysis of Incorrect Options:** * **Option A:** While they ultimately affect viral DNA synthesis, their specific pharmacological classification and primary target is the enzyme Reverse Transcriptase, not direct inhibition of pre-formed viral DNA. * **Option C:** "Group 24" likely refers to **p24**, a viral capsid protein. While HAART reduces the production of all viral components by stopping replication, NRTIs do not directly inhibit the synthesis of p24; Protease Inhibitors are more closely related to the processing of viral proteins. * **Option D:** P53 is a human tumor suppressor protein. Antiretroviral drugs do not function by synthesizing anti-apoptotic molecules; in fact, HIV itself often interferes with p53 to promote cell survival for replication. **Clinical Pearls for NEET-PG:** * **Zidovudine (AZT):** Known for causing **bone marrow suppression** (anemia/neutropenia) and is the drug of choice for preventing **vertical transmission** (mother-to-child). * **Didanosine (ddI):** Classically associated with **pancreatitis** and peripheral neuropathy. * **Mitochondrial Toxicity:** NRTIs can inhibit mitochondrial DNA polymerase-gamma, leading to **lactic acidosis** and hepatic steatosis.

Question 162: What is the drug of choice in a patient with severe complicated falciparum malaria?

A. Chloroquine
B. Quinine
C. Artesunate (Correct Answer)
D. Artemether

Explanation: **Explanation:** **Artesunate** is the current **Drug of Choice (DOC)** for severe or complicated *Plasmodium falciparum* malaria, as recommended by both the WHO and National Guidelines. 1. **Why Artesunate is correct:** Intravenous (IV) Artesunate is a water-soluble artemisinin derivative that acts rapidly against all erythrocytic stages of the parasite (including young rings). It clears parasitemia faster than quinine and significantly reduces mortality rates in both adults (SEAQUAMAT trial) and children (AQUAMAT trial). It also has a superior safety profile with a lower risk of hypoglycemia. 2. **Why other options are incorrect:** * **Chloroquine:** While it was once the mainstay, widespread resistance in *P. falciparum* makes it ineffective for severe cases. It is now primarily used for *P. vivax* (where sensitive). * **Quinine:** Previously the DOC, it is now considered a second-line alternative. It requires slow IV infusion, carries a high risk of **cinchonism**, and frequently causes refractory hypoglycemia due to hyperinsulinemia. * **Artemether:** This is a lipid-soluble derivative usually administered intramuscularly. Its absorption is erratic compared to the rapid bioavailability of IV Artesunate, making it less ideal for emergency stabilization. **High-Yield Clinical Pearls for NEET-PG:** * **Dosing Schedule:** IV Artesunate is given at 0, 12, and 24 hours, then once daily. * **Transition:** Once the patient can tolerate oral medication, a full 3-day course of **ACT (Artemisinin-based Combination Therapy)** must be completed. * **Side Effect:** Watch for **Post-Artesunate Delayed Hemolysis (PADH)**, which can occur 1–3 weeks after treatment. * **Pregnancy:** IV Artesunate is safe and recommended for severe malaria in **all trimesters** of pregnancy.

Question 163: Beta-lactam ring is present in all of the following except?

A. Sulbactam
B. Imipenem
C. Vancomycin (Correct Answer)
D. Cephalexin

Explanation: **Explanation:** The core concept tested here is the structural classification of cell wall synthesis inhibitors. **Beta-lactam antibiotics** are defined by the presence of a four-membered beta-lactam ring, which is essential for their antibacterial activity as it mimics the D-Ala-D-Ala substrate of penicillin-binding proteins (PBPs). **Why Vancomycin is the correct answer:** Vancomycin is a **Glycopeptide** antibiotic, not a beta-lactam. While it also inhibits cell wall synthesis, its mechanism is distinct: it binds directly to the **D-Ala-D-Ala terminus** of the nascent peptidoglycan pentapeptide, sterically hindering polymerization (transglycosylation). It lacks the beta-lactam ring structure entirely. **Analysis of Incorrect Options:** * **Sulbactam:** This is a **Beta-lactamase inhibitor**. Although it has weak intrinsic antibacterial activity, it possesses a beta-lactam ring that allows it to act as a "suicide inhibitor" by binding irreversibly to beta-lactamase enzymes. * **Imipenem:** This belongs to the **Carbapenem** class. Carbapenems are characterized by a beta-lactam ring fused to a five-membered ring system with a carbon at position 1. * **Cephalexin:** This is a **First-generation Cephalosporin**. All cephalosporins contain a beta-lactam ring fused to a six-membered dihydrothiazine ring. **High-Yield Clinical Pearls for NEET-PG:** 1. **Beta-lactam families:** Penicillins, Cephalosporins, Monobactams (e.g., Aztreonam), Carbapenems, and Beta-lactamase inhibitors (Clavulanic acid, Sulbactam, Tazobactam). 2. **Vancomycin "Red Man Syndrome":** An infusion-related reaction caused by direct histamine release (not a true IgE-mediated allergy). 3. **Mechanism of Resistance:** The most common resistance to Vancomycin (VRSA/VRE) involves the alteration of the binding site from **D-Ala-D-Ala to D-Ala-D-Lac**.

Question 164: Which of the following antitubercular drug combinations is preferred in severe liver disease?

A. Streptomycin + Isoniazid
B. Streptomycin + Ethambutol (Correct Answer)
C. Isoniazid + Rifampicin
D. Rifampicin + Ethambutol

Explanation: **Explanation:** The management of tuberculosis in patients with severe liver disease requires avoiding **hepatotoxic** drugs to prevent further hepatic injury. **1. Why Streptomycin + Ethambutol is correct:** Among the first-line anti-tubercular drugs (HRZES), **Streptomycin (S)** and **Ethambutol (E)** are the only two drugs that are **not hepatotoxic**. * **Streptomycin** is an aminoglycoside excreted primarily by the kidneys. * **Ethambutol** is an antimetabolite also primarily excreted via renal mechanisms. In cases of severe liver dysfunction (e.g., cirrhosis or acute hepatitis), the standard hepatotoxic regimen (Isoniazid, Rifampicin, and Pyrazinamide) is contraindicated. A combination of S + E (often supplemented with a fluoroquinolone) is the safest alternative. **2. Why other options are incorrect:** * **Isoniazid (H):** Highly hepatotoxic; it causes hepatitis through its metabolite, acetylhydrazine. * **Rifampicin (R):** Hepatotoxic; it causes cholestatic jaundice and induces microsomal enzymes. * **Pyrazinamide (Z):** The **most hepatotoxic** of all first-line drugs. Options A, C, and D are incorrect because they all contain at least one hepatotoxic agent (H or R), which could precipitate liver failure in a patient with pre-existing severe liver disease. **Clinical Pearls for NEET-PG:** * **Order of Hepatotoxicity:** Pyrazinamide > Isoniazid > Rifampicin. * **Safe in Liver Disease:** Streptomycin, Ethambutol, and Fluoroquinolones (like Levofloxacin). * **Safe in Renal Failure:** Rifampicin and Isoniazid (as they are metabolized by the liver). Ethambutol and Streptomycin require dose adjustment or avoidance in renal failure. * **Visual Side Effect:** Ethambutol causes optic neuritis (check visual acuity/color vision). * **Ototoxicity:** Streptomycin causes vestibulocochlear nerve damage.

Question 165: A patient suffering from AIDS is on Zidovudine, Lamivudine, and Indinavir therapy. He develops pulmonary tuberculosis for which treatment is started. Which of the following antitubercular drugs should be avoided in him?

A. Isoniazid (INH)
B. Ethambutol
C. Pyrazinamide
D. Rifampicin (Correct Answer)

Explanation: ### Explanation The correct answer is **Rifampicin (Option D)**. **1. Why Rifampicin is avoided:** The patient is on a HAART (Highly Active Antiretroviral Therapy) regimen containing **Indinavir**, which is a **Protease Inhibitor (PI)**. Rifampicin is a potent **microsomal enzyme inducer** (specifically Cytochrome P450 3A4). It significantly increases the metabolism of Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), leading to sub-therapeutic plasma levels of these drugs [1]. This can result in treatment failure and the development of drug-resistant HIV strains. **2. Why other options are incorrect:** * **Isoniazid (INH), Ethambutol, and Pyrazinamide:** These drugs do not have significant induction or inhibition effects on the CYP450 enzyme system. They do not interfere with the pharmacokinetics of Indinavir, Zidovudine, or Lamivudine and are considered safe to use in standard doses in HIV-TB co-infection [1]. **3. High-Yield Clinical Pearls for NEET-PG:** * **Rifabutin vs. Rifampicin:** In patients on Protease Inhibitors, **Rifabutin** is the preferred substitute for Rifampicin [1]. It is a much weaker enzyme inducer and has less impact on PI levels [2]. * **Integrase Inhibitors:** If a patient is on **Dolutegravir**, the dose must be doubled (50mg BD instead of OD) if Rifampicin is co-administered. * **Indinavir Side Effect:** Remember that Indinavir is notorious for causing **nephrolithiasis** (kidney stones) and crystalluria; patients must stay well-hydrated. * **Zidovudine Side Effect:** Monitor for **anemia/neutropenia**, as it causes bone marrow suppression. * **Lamivudine:** It is the safest NRTI and is also active against the Hepatitis B virus (HBV).

Question 166: Combination chemotherapy is used in tuberculosis in order to reduce which of the following?

A. Side effects of drugs
B. Cost of therapy
C. Dosage of drugs
D. Development of drug resistance (Correct Answer)

Explanation: **Explanation:** The primary rationale for using combination chemotherapy in Tuberculosis (TB) is to **prevent the development of drug resistance**. *Mycobacterium tuberculosis* undergoes spontaneous chromosomal mutations at a predictable frequency (e.g., 1 in $10^6$ bacilli for Isoniazid and 1 in $10^8$ for Rifampicin). In a typical cavitary TB lesion containing $10^9$ to $10^{12}$ bacilli, monotherapy would inevitably select for resistant mutants, leading to treatment failure. By using multiple drugs with different mechanisms of action simultaneously, the probability of a bacterium developing resistance to all drugs at once becomes mathematically negligible (e.g., $10^{-6} \times 10^{-8} = 10^{-14}$). **Analysis of Incorrect Options:** * **A. Side effects of drugs:** Combination therapy often *increases* the risk of adverse effects (e.g., additive hepatotoxicity of Isoniazid, Rifampicin, and Pyrazinamide). * **B. Cost of therapy:** Using multiple drugs is generally more expensive than using a single agent. * **C. Dosage of drugs:** In TB, drugs are used at their full therapeutic doses; combination therapy does not allow for dose reduction of individual components. **High-Yield Clinical Pearls for NEET-PG:** * **DOTS (Directly Observed Treatment Short-course):** The standard strategy to ensure compliance and prevent resistance. * **Bactericidal vs. Bacteriostatic:** Isoniazid, Rifampicin, Pyrazinamide, and Streptomycin are bactericidal; Ethambutol is primarily bacteriostatic. * **Sterilizing Effect:** Rifampicin and Pyrazinamide are the most effective at killing persistent/dormant bacilli, which helps in preventing relapse and shortening the duration of therapy. * **MDR-TB:** Defined as resistance to at least **Isoniazid and Rifampicin**.

Question 167: What is the primary treatment for Herpes zoster?

A. Zidovudine
B. Valacyclovir (Correct Answer)
C. Ribavirin
D. Nevirapine

Explanation: **Explanation:** **Primary Concept:** Herpes zoster (shingles) is caused by the reactivation of the **Varicella-Zoster Virus (VZV)**. The mainstay of treatment is antiviral therapy using nucleoside analogs that inhibit viral DNA polymerase. **Valacyclovir** is the preferred oral treatment because it is a prodrug of acyclovir with significantly higher oral bioavailability (3–5 times higher), leading to better plasma concentrations and a more convenient dosing schedule (TID vs. 5 times daily for acyclovir). It accelerates the healing of lesions and reduces the duration of post-herpetic neuralgia. **Analysis of Options:** * **A. Zidovudine (AZT):** A Nucleoside Reverse Transcriptase Inhibitor (NRTI) used primarily in the treatment of **HIV/AIDS**. It has no activity against DNA viruses like VZV. * **C. Ribavirin:** A broad-spectrum antiviral used mainly for **Hepatitis C** (in combination with interferon) and **RSV** (Respiratory Syncytial Virus). It is not effective for Herpes viruses. * **D. Nevirapine:** A Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) used exclusively for **HIV-1** infection and prevention of mother-to-child transmission. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Valacyclovir/Acyclovir requires initial phosphorylation by **viral Thymidine Kinase** to become active (Acyclovir monophosphate). This ensures selective toxicity. * **Timing:** Treatment should ideally be initiated within **72 hours** of rash onset to be most effective. * **Drug of Choice for CMV:** Ganciclovir (not acyclovir). * **Foscarnet:** Used for acyclovir-resistant Herpes or CMV; it does *not* require viral thymidine kinase for activation.

Question 168: Which is the most effective antitubercular drug against slow multiplying intracellular mycobacteria?

A. Rifampicin (Correct Answer)
B. Isoniazid
C. Pyrazinamide
D. Ethambutol

Explanation: The effectiveness of antitubercular drugs (ATT) depends on their ability to target specific subpopulations of *Mycobacterium tuberculosis* based on their metabolic activity and location. **1. Why Rifampicin is correct:** Mycobacteria exist in four distinct populations. **Rifampicin** is unique because it is highly effective against **slowly multiplying organisms** (spurters) that reside within caseous material or intracellularly [1], [2]. It inhibits bacterial DNA-dependent RNA polymerase, exerting a potent bactericidal effect even during brief periods of metabolic activity [2]. This makes it the most important drug for preventing relapses (sterilizing action). **2. Why the other options are incorrect:** * **Isoniazid (INH):** While it is the most potent bactericidal drug, it is primarily effective against **rapidly multiplying** extracellular bacilli. It has minimal effect on slow growers. * **Pyrazinamide:** This drug is specifically active against bacilli in an **acidic medium** (intracellularly within macrophages). While it targets a specific niche, Rifampicin is considered more broadly effective against the "slowly multiplying" population across different environments. * **Ethambutol:** This is a **bacteriostatic** drug that inhibits cell wall synthesis. It is the least potent of the first-line drugs [3] and does not have significant sterilizing activity against slow growers. **High-Yield NEET-PG Pearls:** * **Best Sterilizing Action:** Rifampicin > Pyrazinamide. * **Early Bactericidal Activity (EBA):** Isoniazid (highest in the first 48 hours). * **Site of Action:** Pyrazinamide works best at acidic pH; Streptomycin works only at alkaline pH (extracellular). * **Mnemonic for Populations:** * **I**NH = **I**nside cavities (Rapidly growing). * **R**ifampicin = **R**esting/Slowly growing. * **P**yrazinamide = **P**hago-lysosomes (Acidic pH).

Question 169: Which of the following is a protease inhibitor?

A. Lamivudine
B. Saquinavir (Correct Answer)
C. Delavirdine
D. Zidovudine

Explanation: **Explanation:** The question tests the classification of Antiretroviral Therapy (ART) drugs used in the management of HIV. **Correct Option: B. Saquinavir** Saquinavir belongs to the **Protease Inhibitors (PIs)** class [5]. These drugs work by inhibiting the viral enzyme **HIV-1 protease** [4], which is responsible for cleaving precursor polyproteins (Gag-Pol) into functional mature proteins [1]. Inhibition of this enzyme results in the production of immature, non-infectious virions. * **High-Yield Tip:** All Protease Inhibitors typically end with the suffix **"-navir"** (e.g., Ritonavir, Atazanavir, Darunavir) [3]. **Incorrect Options:** * **A. Lamivudine (3TC):** This is a **Nucleoside Reverse Transcriptase Inhibitor (NRTI)**. It is a cytosine analog used in both HIV and Hepatitis B treatment. * **C. Delavirdine:** This is a **Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)** [2]. Unlike NRTIs, NNRTIs bind directly to the reverse transcriptase enzyme at a site different from the active site (allosteric inhibition). * **D. Zidovudine (AZT):** This is the prototype **NRTI** (thymidine analog). It is historically significant as the first drug approved for HIV and is notably used to prevent mother-to-child transmission. **Clinical Pearls for NEET-PG:** 1. **Metabolic Side Effects:** Protease Inhibitors are frequently associated with **lipodystrophy** (buffalo hump), hyperglycemia (insulin resistance), and hyperlipidemia. 2. **Ritonavir Boosting:** Ritonavir is a potent **CYP3A4 inhibitor** [5]. It is often used in low doses not for its antiviral effect, but to "boost" the plasma concentrations of other PIs. 3. **Indinavir:** A specific PI known for causing **nephrolithiasis** (crystalluria).

Question 170: Which of the following is a true statement regarding Rifampicin?

A. Acts by inhibiting mycolic acid synthesis
B. Dose adjustment is needed in renal failure
C. Gets concentrated intracellularly mainly in neutrophils
D. Increased metabolism of cyclosporine when given concomitantly (Correct Answer)

Explanation: **Explanation:** **Correct Option: D (Increased metabolism of cyclosporine when given concomitantly)** Rifampicin is one of the most potent **inducers of the Cytochrome P450 (CYP450) enzyme system** (specifically CYP3A4) [2]. When administered with drugs metabolized by these enzymes—such as **cyclosporine**, oral contraceptives, warfarin, and HIV protease inhibitors—it accelerates their metabolism. This leads to decreased plasma concentrations and therapeutic failure of the co-administered drug. **Analysis of Incorrect Options:** * **A. Acts by inhibiting mycolic acid synthesis:** This is the mechanism of action for **Isoniazid (INH)**. Rifampicin acts by inhibiting **DNA-dependent RNA polymerase**, thereby blocking bacterial RNA synthesis [1], [3]. * **B. Dose adjustment is needed in renal failure:** Rifampicin is primarily metabolized by the liver and excreted mainly through **bile/feces** [1]. Therefore, no dose adjustment is required in renal failure, making it relatively safe for patients with kidney disease [1]. * **C. Gets concentrated intracellularly mainly in neutrophils:** While Rifampicin is lipid-soluble and penetrates cells [1], [3], this specific description (concentration in neutrophils and macrophages) is a hallmark of **Macrolides** (like Azithromycin) and **Ethambutol**. **High-Yield Clinical Pearls for NEET-PG:** * **Secretory Side Effect:** Rifampicin causes harmless **orange-red discoloration** of urine, sweat, tears, and contact lenses (important counseling point). * **Resistance:** Develops rapidly if used as monotherapy due to mutations in the **rpoB gene** [3]. * **Alternative:** **Rifabutin** is preferred over Rifampicin in HIV patients on Protease Inhibitors because it is a less potent enzyme inducer. * **Flu-like syndrome:** Occurs when Rifampicin is taken intermittently (less than twice weekly).

Practice by Chapter

Beta-Lactam Antibiotics

Practice Questions

Aminoglycosides

Practice Questions

Macrolides and Ketolides

Practice Questions

Tetracyclines

Practice Questions

Quinolones

Practice Questions

Sulfonamides and Trimethoprim

Practice Questions

Antimycobacterial Drugs

Practice Questions

Antifungal Agents

Practice Questions

Antiviral Drugs

Practice Questions

Antiparasitic Agents

Practice Questions

Principles of Antimicrobial Selection

Practice Questions

Antimicrobial Resistance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free